REGISTRATION OBTAINED FOR AIVIAL™ IN BULGARIA AND MOLDOVA

In November and December 2023, marketing authorizations were received in respectively Moldova and Bulgaria for Aivial™. Aivial™ has been licensed from Mithra (Belgium) and is widely prescribed for treating menopausal symptoms. Market introductions are expected in the first half of 2024. The marketing authorization for Ukraine is expected in 2024.

About Aivial™

Aivial™ is a synthetic steroid (tibolone) to be used for hormonal replacement therapy. Aivial™ is a bioequivalent of Livial® 2.5mg, which is a product that mimics the activity of the female sex hormones in the body and is used especially for the relief of symptoms occurring during and after menopause. In some countries, this product is also used for the prevention of osteoporosis. It has been demonstrated that tibolone has favourable effects on treating vasomotor symptoms, and improves libido and sexual function, while decreasing unscheduled bleedings, depression and anxiety. Many side effects, common with classical combined hormonal replacement therapy, are absent.